Vision Possible: Why Eyestem Is ‘Bullish’ About Its Dry AMD Candidate

Eyestem’s founder and CEO, Dr Jogin Desai, talks to Scrip about progress made by the firm’s experimental treatment for dry age-related macular degeneration, cell and gene therapy pricing considerations and the wider competitive landscape. The company is also developing treatments for retinitis pigmentosa and idiopathic pulmonary fibrosis.